Hefei Lifeon Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Hefei Lifeon Pharmaceutical has a total shareholder equity of CN¥1.9B and total debt of CN¥59.6M, which brings its debt-to-equity ratio to 3.1%. Its total assets and total liabilities are CN¥2.6B and CN¥630.2M respectively. Hefei Lifeon Pharmaceutical's EBIT is CN¥166.7M making its interest coverage ratio -18. It has cash and short-term investments of CN¥487.6M.
Key information
3.1%
Debt to equity ratio
CN¥59.65m
Debt
| Interest coverage ratio | -18x |
| Cash | CN¥487.65m |
| Equity | CN¥1.92b |
| Total liabilities | CN¥630.16m |
| Total assets | CN¥2.55b |
Recent financial health updates
Recent updates
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 05
Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet
Sep 30Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50
May 23Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump
May 22Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues
Apr 29Financial Position Analysis
Short Term Liabilities: 003020's short term assets (CN¥1.2B) exceed its short term liabilities (CN¥537.8M).
Long Term Liabilities: 003020's short term assets (CN¥1.2B) exceed its long term liabilities (CN¥92.4M).
Debt to Equity History and Analysis
Debt Level: 003020 has more cash than its total debt.
Reducing Debt: 003020's debt to equity ratio has reduced from 4.7% to 3.1% over the past 5 years.
Debt Coverage: 003020's debt is well covered by operating cash flow (449.9%).
Interest Coverage: 003020 earns more interest than it pays, so coverage of interest payments is not a concern.